Table 6.

Association of RAS inhibitor use with cerebral vessel pathologies.

RAS inhibitor use	OR, Estimate (SE, p‐value)
	Atherosclerosis	Arteriolosclerosis	Amyloid angiopathy
During the study	2.056, 0.721 (0.363, 0.047)	0.551, −0.595 (0.375, 0.113)	0.829, −0.188 (0.380, 0.621)
During last 5 years of life	2.129, 0.756 (0.350, 0.031)	0.535, −0.626 (0.368, 0.089)	0.897, −0.109 (0.370, 0.769)

Each linear regression model with individual measure of cerebral vessel pathologies as the outcome has been adjusted for age at death, sex, and diabetes. Bold values denote statistical significance (p < 0.05).